Coreg

Atrial Fibrillation, Ventricular Dysfunction, Left, Heart failure + 5 more

Treatment

9 FDA approvals

20 Active Studies for Coreg

What is Coreg

Carvedilol

The Generic name of this drug

Treatment Summary

Carvedilol is a combination drug used to treat heart failure, left ventricular dysfunction, and high blood pressure. It works by blocking the action of two types of hormones: beta and alpha-1. Carvedilol has been found to be effective in treating moderate cases of hypertension with fewer side effects than higher doses of single drugs. It was approved by the FDA in 1995.

Coreg

is the brand name

image of different drug pills on a surface

Coreg Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Coreg

Carvedilol

1997

522

Approved as Treatment by the FDA

Carvedilol, commonly known as Coreg, is approved by the FDA for 9 uses such as Ventricular Dysfunction, Left and Heart failure .

Ventricular Dysfunction, Left

Helps manage LVEF ≤40% Left ventricular dysfunction

Heart failure

Helps manage NYHA Class I or II heart failure

chronic heart failure with reduced ejection fraction (NYHA Class IV)

Helps manage chronic heart failure with reduced ejection fraction (NYHA Class IV)

NYHA Class I or II heart failure

Helps manage NYHA Class I or II heart failure

Hypesthesia

Helps manage chronic heart failure with reduced ejection fraction (NYHA Class III)

LVEF ≤40% Left ventricular dysfunction

Helps manage LVEF ≤40% Left ventricular dysfunction

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Hypesthesia

Helps manage chronic heart failure with reduced ejection fraction (NYHA Class IV)

Heart Attack

Helps manage Myocardial Infarction

Effectiveness

How Coreg Affects Patients

Carvedilol is a drug used to reduce a rapid heart rate and lower blood pressure. It needs to be taken once a day and is usually given in doses of 10-80mg. It's important to not stop taking carvedilol suddenly, as this can worsen coronary artery disease.

How Coreg works in the body

Carvedilol reduces heart rate and blood pressure by blocking signals sent to the heart and blood vessels by the sympathetic nervous system. It also has antioxidant properties, which can help prevent cholesterol from building up in the heart.

When to interrupt dosage

The prescribed dosage of Coreg is contingent upon the diagnosed state, including Chronic Stable Angina Pectoris, Ventricular Dysfunction, Left and Hypesthesia. The amount of dosage varies, based on the administration method denoted in the table below.

Condition

Dosage

Administration

Atrial Fibrillation

, 10.0 mg, 20.0 mg, 40.0 mg, 80.0 mg, 3.125 mg, 6.25 mg, 12.5 mg, 25.0 mg, 0.125 mg, 50.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Kit, Tablet, coated, Tablet, coated - Oral

Ventricular Dysfunction, Left

, 10.0 mg, 20.0 mg, 40.0 mg, 80.0 mg, 3.125 mg, 6.25 mg, 12.5 mg, 25.0 mg, 0.125 mg, 50.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Kit, Tablet, coated, Tablet, coated - Oral

Heart failure

, 10.0 mg, 20.0 mg, 40.0 mg, 80.0 mg, 3.125 mg, 6.25 mg, 12.5 mg, 25.0 mg, 0.125 mg, 50.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Kit, Tablet, coated, Tablet, coated - Oral

Hypesthesia

, 10.0 mg, 20.0 mg, 40.0 mg, 80.0 mg, 3.125 mg, 6.25 mg, 12.5 mg, 25.0 mg, 0.125 mg, 50.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Kit, Tablet, coated, Tablet, coated - Oral

Hypesthesia

, 10.0 mg, 20.0 mg, 40.0 mg, 80.0 mg, 3.125 mg, 6.25 mg, 12.5 mg, 25.0 mg, 0.125 mg, 50.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Kit, Tablet, coated, Tablet, coated - Oral

Heart Attack

, 10.0 mg, 20.0 mg, 40.0 mg, 80.0 mg, 3.125 mg, 6.25 mg, 12.5 mg, 25.0 mg, 0.125 mg, 50.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Kit, Tablet, coated, Tablet, coated - Oral

Hypertensive disease

, 10.0 mg, 20.0 mg, 40.0 mg, 80.0 mg, 3.125 mg, 6.25 mg, 12.5 mg, 25.0 mg, 0.125 mg, 50.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Kit, Tablet, coated, Tablet, coated - Oral

Angina, Stable

, 10.0 mg, 20.0 mg, 40.0 mg, 80.0 mg, 3.125 mg, 6.25 mg, 12.5 mg, 25.0 mg, 0.125 mg, 50.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Kit, Tablet, coated, Tablet, coated - Oral

Warnings

Coreg has nine contra-indications and its utilization should be avoided in combination with the situations specified in the table below.

Coreg Contraindications

Condition

Risk Level

Notes

Bronchospasm

Do Not Combine

Asthma

Do Not Combine

Sick Sinus Syndrome

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Therapeutic procedure

Do Not Combine

Therapeutic procedure

Do Not Combine

severe bradycardia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Carvedilol may interact with Pulse Frequency

Atrioventricular Block

Do Not Combine

There are 20 known major drug interactions with Coreg.

Common Coreg Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Carvedilol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Carvedilol.

Abediterol

Major

The therapeutic efficacy of Abediterol can be decreased when used in combination with Carvedilol.

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Carvedilol.

Acepromazine

Major

Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Coreg Toxicity & Overdose Risk

Those who overdose on the drug may have low blood pressure, slow heartbeats, heart problems, and even cardiac arrest. The patient should be placed in a lying position and can be given atropine for slow heartbeats and glucagon with sympathomimetics to support the cardiovascular system.

image of a doctor in a lab doing drug, clinical research

Coreg Novel Uses: Which Conditions Have a Clinical Trial Featuring Coreg?

253 active clinical trials are being conducted to assess the potential of Coreg in providing relief for Hypesthesia, Heart failure and Hypesthesia.

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

103 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2, Early Phase 1

Hypertensive disease

41 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

Heart Attack

25 Actively Recruiting

Not Applicable, Early Phase 1, Phase 4, Phase 2, Phase 3

Angina, Stable

0 Actively Recruiting

Hypesthesia

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Heart failure

0 Actively Recruiting

Hypesthesia

4 Actively Recruiting

Not Applicable, Phase 1

Ventricular Dysfunction, Left

0 Actively Recruiting

Coreg Reviews: What are patients saying about Coreg?

5

Patient Review

3/25/2018

Coreg for High Blood Pressure

I began taking Coreg at age 58-59. I was prescribed 12.5 mg twice a day, but experienced some side effects in the form of tiredness. This problem was resolved by taking a 20 mg time-released prescription. It's important to note that I only use brand name Coreg; thegeneric version may not be as effective. I also take lisinipril (generic) and an old generic water pill for my blood pressure. The water pill is a big problem because it makes me have to drink more water and avoid salt, but it does bring my blood pressure down well.

5

Patient Review

12/17/2019

Coreg for Chronic Heart Failure

I've been on this treatment for two decades and it's really kept me alive and well. I would highly recommend it to others in a similar situation as me.

5

Patient Review

7/25/2019

Coreg for Chronic Heart Failure

Coreg has been a lifesaver for me since I was diagnosed with heart failure post chemotherapy. My dose is low, at 6.25 mg twice a day, but it keeps my blood pressure in check and has helped me manage my symptoms effectively.

5

Patient Review

12/17/2019

Coreg for Chronic Heart Failure

I've been taking this medication for 20 years now and it's really kept me going. I don't know how I would have fared without it, but I'm grateful that it hasn't caused any organ damage.

5

Patient Review

10/14/2017

Coreg for High Blood Pressure

I had no issues with this treatment. My blood pressure is now more stable than ever.

4.7

Patient Review

11/19/2017

Coreg for Chronic Heart Failure

Though there are some not-so-fun side effects that come with this treatment, they pale in comparison to how well it's worked for me. I was diagnosed in 2003 and am still going strong!

2.7

Patient Review

12/31/2018

Coreg for High Blood Pressure

After taking Carvedilol for 9 years, I have now been diagnosed with stage 3 kidney disease. I believe it is this medication that has caused this medical problem. My nephologist has cut my pills from two per day to 1/2 twice a day. I want off of Carvedilol as it has ruined my life.

2.3

Patient Review

8/15/2016

Coreg for High Blood Pressure

I have only taken carvedilol for 3 days and I have my head and chest pound when I get up or it is near time for the next dose. I have had a non-stop headache, nausea and a metallic taste in my mouth. I will give it til Friday for improvement. If none I will talk to my doctor about changing.

2

Patient Review

2/5/2017

Coreg for High Blood Pressure

I experienced fatigue, dizziness and headaches. I also started to notice tenderness in my gums and nasal passages.

1.7

Patient Review

2/29/2016

Coreg for High Blood Pressure

Just a week in and I am already feeling the adverse effects of this medication. I'm exhausted, my mouth is blistered and swollen, and my head hurts. My pupils are so dilated that it's hard to see. I also have no control over my bladder and I'm sore all over. This has been miserable.

1.7

Patient Review

12/7/2018

Coreg for High Blood Pressure

I experienced intense exhaustion, swelling of legs, and extreme difficulty breathing while on this medication. I also lost sleep due to my breathing difficulties, which led to body pain and depression. My thinking was also very unclear, and I felt anxious all the time. This drug was a nightmare for me.

1.7

Patient Review

2/27/2017

Coreg for High Blood Pressure

I'm always tired and unable to focus while on this medication, which is not worth the benefit in my opinion.

1

Patient Review

2/18/2017

Coreg for Chronic Heart Failure

This drug is terrible. My mother was sent home from the hospital with it, and after the first dose she developed shortness of breath and a violent cough. It was so bad that she couldn't breathe, and I thought we were going to lose her.

1

Patient Review

7/9/2017

Coreg for High Blood Pressure

I felt really exhausted after taking this, to the point where it was hard to focus or think clearly. I also had a lot of trouble sleeping, and my knee joints started hurting pretty badly.

1

Patient Review

11/6/2020

Coreg for High Blood Pressure

After only taking this medication for three days, my blood pressure spiked to an incredibly dangerous level. I had to go to the ER and get a bunch of tests done. The only conclusion was that I shouldn't take this drug again, and I definitely won't be.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about coreg

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Coreg a good blood pressure medication?

"Carvedilol, sold under the brand name Coreg among others, is a medication used for treating high blood pressure, heart failure, and left ventricular dysfunction."

Answered by AI

What is the drug Coreg used for?

"Carvedilol is used to treat high blood pressure and heart failure. It can also be used after a heart attack to improve the chances of survival if your heart isn't pumping well. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems."

Answered by AI

What are the most common side effects of carvedilol?

"If you experience any of the following symptoms, you may be allergic to the medication: chest pain, discomfort, tightness, or heaviness; dizziness, lightheadedness, or fainting; generalized swelling or swelling of the feet, ankles, or lower legs; pain; shortness of breath; slow heartbeat; weight gain."

Answered by AI

What are the side effects of taking Coreg?

"Coreg may have a number of serious side effects, including low blood pressure, chest pain, an irregular heartbeat, difficulty breathing and swallowing, hives or a rash, swelling, and fainting. People with liver problems should not take Coreg."

Answered by AI

Clinical Trials for Coreg

Image of Allegheny General Hospital in Pittsburgh, United States.

Bachmann's Bundle vs Right Atrial Appendage Pacing for Atrial Fibrillation

18+
All Sexes
Pittsburgh, PA

Participants will be randomly assigned to one of two clinical treatment Arms, both of which are standard care procedures performed in the right atrium (RA): Arm A: Pacing from the Bachmann's Bundle (BB) in the right atrium (upper right chamber of the heart) Arm B: Pacing from the right atrial appendage (RAA - a sac attached to the right atrium) Neither of these treatments are experimental; both are routinely performed by Electrophysiologists in the clinical setting. The purpose of this study is to compare side by side these two treatments and evaluate if one is better than the other. After the procedure, participants will be followed for one year. Medical record data will be collected, and a blood sample will be collected upon enrollment and at one year after implantation. Research-related surveys will be completed at the standard-care 3-, 6-, and 12-month visits.

Recruiting
Has No Placebo

Allegheny General Hospital

Joshua Silverstein, MD

Medtronic

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Barber and Pharmacist Coordination for High Blood Pressure

35 - 79
Male
Los Angeles, CA

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Christine Albert, MD, MPH

Image of Foothills Medical Center in Calgary, Canada.

Spinal Cord Stimulation for High Blood Pressure

18+
All Sexes
Calgary, Canada

High blood pressure, also called hypertension, raises the risk of heart disease, stroke, and kidney disease. Medications work well for many people, but some people still have blood pressure that stays too high, or they have side effects from their medications. Researchers are looking for treatments that do not involve taking more medication. Nerves help control blood pressure by changing how blood vessels tighten and how hard the heart pumps. Because of this, treatments that act on nerves may be able to lower blood pressure. Spinal cord stimulation is a treatment already used to manage long-term pain. It uses a small device, placed under the skin during a standard operation, that sends mild electrical signals to the spine. Laboratory studies suggest that stimulating the lower part of the mid-back may also lower blood pressure, but this has not been carefully studied in people who already use these devices. This study will look at whether changing the settings on a spinal cord stimulator affects blood pressure. About 11 adults who have high blood pressure and who already have a spinal cord stimulator for long-term pain. No new device will be placed, and no surgery or other invasive procedure will be done for this study. Participants attend a series of study visits. At each visit, trained staff record blood pressure and heart rate while the stimulator is turned on, turned off, and set to other settings that the person's care team has approved and that the person finds comfortable. There are rest breaks between each setting. Over successive visits, the study team works to identify the settings that best lower blood pressure. Participants can stop at any time, and their usual settings are restored at the end of each visit. The study will also look at whether this kind of testing is practical and comfortable for participants. The results will help researchers decide whether larger studies of spinal cord stimulation for blood pressure control are worth doing.

Waitlist Available
Has No Placebo

Foothills Medical Center

Aaron Phillips, PhD

Have you considered Coreg clinical trials?

We made a collection of clinical trials featuring Coreg, we think they might fit your search criteria.
Go to Trials
Image of Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington in Arlington, United States.

Alcohol Abstinence for High Blood Pressure

26 - 49
All Sexes
Arlington, TX

The purpose of this study is to learn whether avoiding alcohol can improve heart and blood vessel health in adults who regularly drink alcohol and have high blood pressure. High blood pressure is a major risk factor for cardiovascular disease (CVD), including heart attack and stroke. In this randomized, controlled trial, men and women aged 26 to 49 years who regularly consume alcohol and have high blood pressure will be assigned by chance to either stop drinking alcohol or continue their usual drinking habits for 8 weeks. Researchers will compare changes in blood pressure and other cardiovascular disease risk factors between the two groups. The information gained from this study may help researchers and health care providers better understand the effects of alcohol consumption on cardiovascular health and whether alcohol abstinence can reduce heart disease risk, especially in adults with high blood pressure.

Recruiting
Has No Placebo

Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington

Image of Department of Family & Community Medicine; University of Alabama at Birmingham in Birmingham, United States.

Treatment for High Blood Pressure

18+
All Sexes
Birmingham, AL

The researchers will invite 30 patients in primary care who have high blood pressure to participate in this health program with a supportive partner of their choosing (these will be the "participant pairs"). Participant pairs will be invited to complete the Heart Care Pairs health program that will include up to six sessions each including 1) some education on a health habit like physical activity and heart healthy foods, 2) goal setting together, and 3) talk about healthy communication to support one another with heart healthy habits. The researchers will work with participants to address things that get in the way of coming for visits like offering transportation and offering telehealth visits. The researchers are seeing how this program works in real life so participants will be asked to complete as many sessions as they want to and can attend. The researchers will be interested in what participants think about the sessions, if they were satisfied with the visits, and if they would recommend the program to others in their community. The researchers will ask these questions in interviews with participants. The researchers will also ask up to 25 primary care workers about how they view the program as helpful to their work with patients with high blood pressure and whether they would refer more patients to the program in the future.

Waitlist Available
Has No Placebo

Department of Family & Community Medicine; University of Alabama at Birmingham

Image of London Health Sciences Centre (LHSC) in London, Canada.

BASIC-S Intervention for Cardiovascular Risk

18+
All Sexes
London, Canada

Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed BASIC-S (Blood Pressure, Activity, Sleep, Interaction, Consumption, and Support), a framework targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.

Waitlist Available
Has No Placebo

London Health Sciences Centre (LHSC)

Have you considered Coreg clinical trials?

We made a collection of clinical trials featuring Coreg, we think they might fit your search criteria.
Go to Trials
Image of University of California, Davis in Sacramento, United States.

EchoPixel HTG for Structural Heart Conditions

18+
All Sexes
Sacramento, CA

To investigate and evaluate the benefits of adding EchoPixel Holographic Therapy Guidance to the current standard of care in Structural Heart (SH) procedures. Current structural heart (SH) procedures rely on standard image guidance (SIG) relies on 2D X-plane or multiplanar reformatted (MPR) views that can conceal critical anatomy elements at the time of implant or therapy delivery which are crucial to achieve an optimal long term durable outcome. This limitation complicates an operator's task of optimally implanting a 3D device, delivered by tools that rotate and maneuver in 3D, within a dynamic 3D anatomy, the heart. Slight mismatches between the device and the target in the heart are indicative of a sub-optimal device position, a key risk-factor of peri-device leak (PDL) and other complications. The primary objective of the study is to determine if including EchoPixel - HTG as an additive visualization procedural tool has a positive impact on optimal procedure outcomes for patients undergoing in Structural Heart (SH) procedures.

Waitlist Available
Has No Placebo

University of California, Davis

Gagan D Singh, MD

EchoPixel, Inc.

Image of NeuroFit Lab, Ivor Wynne Centre, McMaster University in Hamilton, Canada.

Isometric Handgrip Exercise for High Blood Pressure

65+
All Sexes
Hamilton, Canada

The goal of this clinical trial is to evaluate whether a short, supervised isometric handgrip exercise program is feasible and acceptable for older adults with elevated blood pressure or hypertension. It will also explore whether this type of exercise may improve blood pressure and cognitive function. The main questions it aims to answer are: * Is this handgrip exercise program practical and acceptable for older adults to participate in within a community exercise setting? * Does participation in the program lead to changes in blood pressure and cognitive function? Researchers will compare two handgrip devices to determine whether the method of delivering the exercise influences feasibility and outcomes. Participants will: * Be randomly assigned to use one of two handgrip devices. * Complete supervised exercise sessions twice per week for 4 weeks. * Perform brief handgrip contractions at a set intensity during each session. * Complete blood pressure and cognitive assessments before and after the program.

Recruiting
Has No Placebo

NeuroFit Lab, Ivor Wynne Centre, McMaster University (+1 Sites)

Jennifer Heisz, PhD

Image of North Shore University Hospital in Manhasset, United States.

CT Scan for Atrial Fibrillation

18+
All Sexes
Manhasset, NY

This study aims to investigate whether a quick, additional CT scan of the heart, performed immediately after a standard CT scan for pulmonary embolism, can effectively detect blood clots in the left atrial appendage (LAA) in patients with atrial fibrillation. Detecting these clots is crucial before certain heart procedures to prevent stroke. Currently, a different, more involved procedure (Transesophageal Echocardiography - TEE) is often used. This study will assess if this additional CT scan is feasible, meaning if it can provide clear enough images to identify LAA clots without needing more contrast dye. The study will involve 60 patients, half receiving an "ungated" CT scan and the other half a "gated" CT scan (timed with their heart rhythm). The results of these scans will not be used for immediate patient care during the study, but rather to evaluate the CT scan technique itself. There is no direct benefit to participants, but the information gained could lead to faster diagnosis and reduced unnecessary testing for future patients.

Waitlist Available
Has No Placebo

North Shore University Hospital

Canon Medical Systems, USA

Image of SEC Clinical Research in Dothan, United States.

REGN7508 + Apixaban for Atrial Fibrillation

18+
All Sexes
Dothan, AL

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Phase 3
Recruiting

SEC Clinical Research (+43 Sites)

Clinical Trial Management

Regeneron Pharmaceuticals

Have you considered Coreg clinical trials?

We made a collection of clinical trials featuring Coreg, we think they might fit your search criteria.
Go to Trials